CFTR and cystic fibrosis: Therefore, preclinical development and testing of new therapies targeting rare CFTR mutations that do not respond to current CFTR modulators, or for which responsiveness remains unknown due to their low occurrence, remains important to further improve precision medicine and ultimately provide effective therapies for all patients with CF.